ABOUT TRIAXIA

TriAxia provides value to biopharmas by marrying patient clinical and genomic data to provide insights available nowhere else

The Data Problem in Rare Disease

Rare diseases are difficult to study because even large hospitals serve small numbers of patients, and genetic data is often separated from clinical data – denying researchers a complete picture

Our Clinico-Genomic Insights Solution

1. Collaborate with leading hospitals to aggregate and harmonize clinical EHR data

2. Integrate it with DNA and RNA sequence data from consented patient samples

3. Provide AI-driven insights to enable rare disease research, drug development, and patient care

The Growing Demand for Rare Disease Data

Rare disease real world data represents a $20B market growing at a 17% CAGR

Rare disease biopharma market $230B and growing at a 12% CAGR

Our Traction with Major Partners

TriAxia has aggregated and harmonized clinical data for over 80K rare pulmonary disease patients across six health systems, published in ATS, CHEST, WSPH and elsewhere and conducted multiple studies using clinical and/or genomic data in PAH and PH-ILD for multiple leading biopharmas in the rare pulmonary disease space